UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): ~~February~~September 28, 2007

~~The~~Orchestra ~~Immune~~Therapeutics, ~~Response Corporation~~Inc. __________________________________________ (Exact name of registrant as specified in its charter)


Delaware	000-18006	33-0255679
_____________________ (State or other jurisdiction	_____________ (Commission	______________ (I.R.S. Employer
of incorporation)	File Number)	Identification No.)

5931 Darwin Court, Carlsbad, California		92008
_________________________________ (Address of principal executive offices)		___________ (Zip Code)


Registrant’s telephone number, including area code:		(760) 431-7080

Not Applicable
______________________________________________
Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[  ]  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[  ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[  ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[  ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Top of the Form

Item 31.0201 ~~Unregistered~~Entry ~~Sales~~into ofa ~~Equity~~Material ~~Securities~~Definitive Agreement.

AsOn ~~previously~~September ~~reported~~28, in2007, ~~March~~Spencer ~~2006~~Trask weInvestment ~~closed~~Partners aLLC ~~private~~("STIP") ~~placement~~made ofa ~~secured convertible notes and warrants to accredited investors. The notes had an aggregate original principal amount of~~ $8162,000~~,000.~~ ~~The~~investment ~~conversion~~in ~~price of~~ the ~~notes~~Company. In isexchange ~~(giving~~STIP ~~effect~~received toa ~~our~~Senior ~~December~~Subordinated ~~2006~~Secured ~~1-for-100~~Promissory ~~reverse~~Note, ~~stock~~due ~~split)~~on ~~$2.00~~January ~~per~~1, ~~share.~~2008 ~~The noteholders also received warrants entitling them to~~ (~~giving~~the ~~effect~~"STIP toNote") ~~our~~in ~~December~~the ~~2006~~principal ~~1-for-100~~amount ~~reverse~~of ~~stock~~$486,000 ~~split)~~as ~~purchase~~well 12as 648,000~~,000~~ shares of ~~our~~ common stock atof ~~$2.00~~the ~~per share~~Company. The ~~warrants~~STIP ~~are~~Note ~~divided~~and ~~into~~shares ~~two~~of ~~tranches,~~common ~~each~~stock ~~consisting~~were ofissued ~~warrants~~pursuant to ~~(giving~~a ~~effect~~Securities toPurchase ~~our~~Agreement ~~December~~between ~~2006~~the ~~1-for-100~~Company ~~reverse~~and ~~stock~~Spencer ~~split)~~Trask, ~~purchase~~dated 6September 28,~~000~~ 2007,~~000~~ ~~shares. The~~and ~~unexercised~~is ~~warrants~~secured ~~from~~by the ~~first~~grant ~~tranche~~of ~~expired~~a onsecurity ~~August~~interest 7,in ~~2006.~~all Onof ~~February~~the ~~28,~~assets ~~2007 one noteholder converted $12,500~~ of ~~outstanding~~the ~~principal~~Company ~~balance~~pursuant ~~plus~~to ~~accrued~~the ~~interest~~terms of ~~$1,031~~a ~~into~~Security 6Agreement,~~766~~ ~~shares~~dated ofthe ~~common~~same ~~stock~~date, ~~pursuant~~by to the ~~terms~~Company ofin ~~the~~favor ~~notes~~of atSpencer $2Trask.00 On ~~per~~August ~~share.The~~28, 62007,~~766~~ ~~note~~the ~~conversion~~Company ~~shares~~also ~~were~~entered ~~issued~~into toa ~~the~~Registration ~~accredited~~Rights ~~investor~~Agreement ~~noteholder~~with ~~pursuant~~Spencer Trask. Pursuant to the ~~Securities~~Registration ~~Act~~Rights ~~Section~~Agreement, ~~3(a)(9)~~the ~~registration~~Company ~~exemption.After~~agreed ~~the~~to ~~February~~register ~~28,~~Spencer ~~2007~~Trask’s ~~note~~shares ~~conversion,~~of ~~the~~common ~~aggregate~~stock ~~outstanding~~issued ~~principal~~under ~~balance~~the ofSecurities ~~the~~Purchase ~~notes~~Agreement isunder ~~$5,405,000~~certain circumstances.

Certain statements in this Current Report on Form 8-K constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. To the extent that any statements made in this Current Report on Form 8-K contain information that is not historical, such statements are essentially forward-looking and are subject to certain risks and uncertainties, including the risks and uncertainties discussed from time to time in the Company's filings with the SEC, including its Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Any forward-looking statements included in this Current Report on Form 8-K are made as of the date hereof only, based on information available to the Company as of the date hereof, and, subject to any applicable law to the contrary, the Company assumes no obligation to update any forward-looking statements.

Top of the Form

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	The Immune Response Corporation
	Orchestra Therapeutics, Inc.
March 6, 2007	By:	/s/ Michael K. Green
October 2, 2007	By:	Michael K Green
		Name: Michael K. Green
		Name: Michael K Green
		Title: Chief Operating Officer and Chief Financial Officer
		Title: President

Filing Compare · ORCHESTRA THERAPEUTICS, INC.